Description of Clinical Trial

Institution

Start Date

Projected End Date

Planned Number of Patients in Trial

Study Objective

Clinical Update

Expected Date of Preliminary Efficacy Signal

NCT No.

Remaining Financial Contractual Commitment

LB-100 combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2)

MD Anderson

January 2024

December 2027

21

Determine the OS of patients with recurrent ovarian clear cell carcinoma

16 patients entered

December 2026

NCT06065462

$

-0- (1 )

LB-100 combined with atezolizumab in microsatellite stable metastatic colorectal cancer (Phase 1b)

Netherlands Cancer Institute (NKI)

August 2024

December 2026

37

Determine RP2D with atezolizumab

First patient entered August 2024, in total two patients entered

June 2026

NCT06012734

-0- (1 )

LB-100 combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b)

GEIS

June 2023

Recruitment completed September 2024

14

Determine MTD and RP2D

Fourteen patients entered

December 2025

NCT05809830

293,000

Total

$

293,000